Aurovitas Pharma Taizhou Co., Ltd. was established in China Medical City in January 2018, with a registered capital of USD 90.8 million. Aurovitas is primarily engaged in the production and R&D of OSD. The plant covers an area of approximately 97 mu, including production and auxiliary facilities such as quality block and OSD production workshop.